Spero Therapeutics reported a significantly wider net loss in Q3 2026, primarily due to a substantial upfront payment for a new licensing agreement. Despite the increased burn, the company extended its cash runway significantly, which could be viewed positively by investors looking at long-term stability.
Spero Therapeutics announced a net loss of $44.3 million for Q3 2026, a substantial increase from $7.4 million in Q3 2025. This wider loss was largely driven by a $35 million upfront payment for a licensing agreement with Innovent, which also caused R&D expenses to surge. The company also reported no revenue, down from $5.4 million in the prior year. While the immediate financial results are negative, the company's cash position of $107.9 million is now projected to fund operations into the second half of 2029, a significant extension that could alleviate near-term liquidity concerns. This suggests a short-term negative reaction to the earnings miss, but a potential long-term positive for stability and future pipeline development, particularly in immune-mediated diseases.